论文部分内容阅读
为评价多沙唑嗪治疗良性前列腺增生(BPH)导致的膀胱流出道梗阻的有效性和耐受性。Chapple CR等进行了一项安慰剂对照研究。入选了135名有症状且经尿流动力学证实的BPH患者,经过最初2周的基线评价后,其中67名患者和68名患者分别给予多沙唑嗪和安慰剂治疗12周。以尿流动力学和症状为主要指标评估有效性,同时监测血压和药物不良事件。共122名患者(多沙唑嗪组60名,安慰剂组62名)的临床资料可供分析。多沙唑嗪组平均尿流率和最大尿流率分别增加达1
To evaluate the efficacy and tolerability of doxazosin in bladder outlet obstruction caused by benign prostatic hyperplasia (BPH). A placebo-controlled study was conducted by Chapple CR et al. A total of 135 patients with symptomatic and urodynamically confirmed BPH were enrolled. Of the 67 patients and 68 patients treated with doxazosin and placebo for 12 weeks after the initial 2 weeks of baseline evaluation. Validity of urodynamic and symptom assessment was used to assess blood pressure and adverse drug events. A total of 122 patients (doxazosin group 60, placebo group 62) clinical data for analysis. The average urinary flow rate and the maximum urinary flow rate in the doxazosin group increased by 1